Ardelyx, Inc. (ARDX) stock

ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value

$3.09−0.03 (-0.96%)

Close on Nov 13, 2026Market cap $769.99MP/E –Yield –

Ardelyx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Ardelyx's ebitda for the twelve months ending Jun 30, 2026 was -$32.11M. For fiscal 2025 it was -$37.92M. The highest annual figure on record is -$1.26M in fiscal 2014.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$37.92M	–
FY2024	Dec 31, 2024	-$25.89M	–
FY2023	Dec 31, 2023	-$61.98M	–
FY2022	Dec 31, 2022	-$62.62M	–
FY2021	Dec 31, 2021	-$151.54M	–
FY2020	Dec 31, 2020	-$88.24M	–
FY2019	Dec 31, 2019	-$88.76M	–
FY2018	Dec 31, 2018	-$88.25M	–
FY2017	Dec 31, 2017	-$62.52M	–
FY2016	Dec 31, 2016	-$111.60M	–
FY2015	Dec 31, 2015	-$28.59M	–
FY2014	Dec 31, 2014	-$1.26M	–
FY2013	Dec 31, 2013	-$2.27M	–
FY2012	Dec 31, 2012	-$8.13M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	-$11.82M	–
Q1 FY2026	Mar 31, 2026	-$31.88M	–
Q4 FY2025	Dec 31, 2025	$6.02M	-30.3%
Q3 FY2025	Sep 30, 2025	$5.57M	+100.7%
Q2 FY2025	Jun 30, 2025	-$13.76M	–
Q1 FY2025	Mar 31, 2025	-$35.75M	–
Q4 FY2024	Dec 31, 2024	$8.64M	–
Q3 FY2024	Sep 30, 2024	$2.78M	-63.9%
Q2 FY2024	Jun 30, 2024	-$13.06M	–
Q1 FY2024	Mar 31, 2024	-$24.24M	–
Q4 FY2023	Dec 31, 2023	-$27.62M	-325.1%
Q3 FY2023	Sep 30, 2023	$7.69M	–
Q2 FY2023	Jun 30, 2023	-$15.98M	–
Q1 FY2023	Mar 31, 2023	-$26.07M	–
Q4 FY2022	Dec 31, 2022	$12.27M	–
Q3 FY2022	Sep 30, 2022	-$21.60M	–
Q2 FY2022	Jun 30, 2022	-$25.94M	–
Q1 FY2022	Mar 31, 2022	-$27.34M	–
Q4 FY2021	Dec 31, 2021	-$34.78M	–